Immucell Revenue Growth Rates (ICCC), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Immucell Corporation  (NASDAQ: ICCC)
 

ICCC's Revenue Growth by Quarter and Year

Immucell's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ICCC Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 7.19
1st Quarter March 9.66
FY 16.85

ICCCs Annual Revenue
Immucell's Revenue in the fiscal year 2025 $ 27.45 millions
Immucell's Revenue in the fiscal year 2024 $ 26.49 millions
Immucell's Revenue in the fiscal year 2023 $ 17.47 millions
Immucell's Revenue in the fiscal year 2022 $ 18.57 millions
Immucell's Revenue in the fiscal year 2021 $ 19.24 millions




ICCC Revenue second quarter 2026 Y/Y Growth Comment
Immucell Corporation reported Revenue increase of 11.59% year on year in the second quarter 2026, to $ 7.19 millions, this is lower than Immucell Corporation's recent average Revenue increase of 16.09%.

Looking into second quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 5 other companies have achieved higher Revenue growth. While Immucell Corporation' s Revenue growth of 11.59% ranks overall at the positon no. 1555 in the second quarter 2026.


ICCC Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -15.51 % 75.69 % 30.43 %
3rd Quarter September - -10.82 % 14.04 % 9.79 %
2nd Quarter June 11.59 % 23.14 % 72.04 % -21.24 %
1st Quarter March 19.7 % 28.1 % 82.61 % -42.5 %
FY   - 3.55 % 57.18 % -

Financial Statements
Immucell's second quarter 2026 Revenue $ 7.19 millions ICCC's Income Statement
Immucell's second quarter 2025 Revenue $ 6.44 millions Quarterly ICCC's Income Statement


ICCC Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 41.23 % 49.08 % -3.23 %
3rd Quarter September - -16.77 % 14.91 % 73.36 %
2nd Quarter June -25.61 % -20.2 % -16.98 % -11.88 %
1st Quarter March 27.61 % -9.93 % 23.53 % -11.76 %
FY (Year on Year)   - 3.55 % 57.18 % -


Back to ICCC Growth rate Comparisons >> Back to ICCC Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #259
Overall #1555

Revenue Y/Y Growth Statistics
High Average Low
82.66 % 16.09 % -42.55 %
(Dec 31 2024)   (Jun 30 2023)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #259
Overall #1555
Revenue Y/Y Growth Statistics
High Average Low
82.66 % 16.09 % -42.55 %
(Dec 31 2024)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Immucell's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
122.27 % 6.7 % -50.63 %
(Dec 31 2019)  


ICCC's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Immucell Corporation disclosed fall in Revenue from the first quarter by -25.61% to $ 7.19 millions, from $ 9.66 millions achived in the previous reporting period.

But that's not important problem, as Immucell's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Immucell's Revenue growth quarter on quarter, overall rank is 3364.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #11
Healthcare Sector #468
Overall #3364
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #11
Healthcare Sector #468
Overall #3364
Revenue Q/Q Growth Statistics
High Average Low
122.27 % 6.7 % -50.63 %
(Dec 31 2019)  


ICCC's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Immucell Corporation disclosed fall in Revenue from the first quarter by -25.61% to $ 7.19 millions, from $ 9.66 millions achived in the previous reporting period.

But that's not important problem, as Immucell's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Immucell's Revenue growth quarter on quarter, overall rank is 3364.


Immucell's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 29.78 $ 29.04 $ 27.45 $ 28.83 $ 29.48
Y / Y Revenue Growth (TTM) 1.01 % 2.73 % 3.59 % 27.38 % 34.68 %
Year on Year Revenue Growth Overall Ranking # 477 # 231 # 158 # 181 # 399
Seqeuential Revenue Change (TTM) 2.55 % 5.79 % -4.81 % -2.2 % 4.3 %
Seq. Revenue Growth (TTM) Overall Ranking # 2156 # 1602 # 776 # 664 # 972


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Immucell's cumulative twelve months Revenue were $ 30 millions, company would post below average annual Revenue growth of 4.3% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Immucell's Revenue growth from the 9.66% growth in Mar 31 2026.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 231 to 477.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 5
Healthcare Sector # 114
Overall # 477

Revenue TTM Y/Y Growth Statistics
High Average Low
57.2 %
 17.73 %
-25.7 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 321
S&P 500 # 2156
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Immucell's cumulative twelve months Revenue were $ 30 millions, company would post below average annual Revenue growth of -25.7% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Immucell's Revenue growth from the 9.66% growth in Mar 31 2026.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 231 to 477.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 5
Healthcare Sector # 114
Overall # 477

Revenue TTM Y/Y Growth Statistics
High Average Low
57.2 %
17.73 %
-25.7 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 321
S&P 500 # 2156




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ICCC's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Castle Biosciences Inc 20.14%$ 20.140 millions
Procept Biorobotics Corporation20.00%$ 20.004 millions
Biomarin Pharmaceutical Inc19.91%$ 19.905 millions
Cannapharmarx Inc 19.26%$ 19.261 millions
Anika Therapeutics Inc 19.18%$ 19.176 millions
Bioaffinity Technologies Inc 18.99%$ 18.992 millions
Aurinia Pharmaceuticals Inc 18.87%$ 18.872 millions
Camp4 Therapeutics Corporation18.84%$ 18.838 millions
Lensar Inc 18.37%$ 18.371 millions
Immunocore Holdings Plc18.34%$ 18.336 millions
Innovage Holding Corp 18.31%$ 18.307 millions
Koru Medical Systems Inc 18.15%$ 18.153 millions
Clearpoint Neuro Inc 18.07%$ 18.068 millions
Avita Medical Inc 17.83%$ 17.830 millions
Xencor Inc17.46%$ 17.458 millions
Logicmark Inc17.39%$ 17.387 millions
Ensign Group Inc17.33%$ 17.325 millions
Medpace Holdings Inc 17.24%$ 17.242 millions
Geron Corporation17.22%$ 17.220 millions
Si bone inc 17.16%$ 17.159 millions
Cvrx inc 16.77%$ 16.766 millions
Regeneron Pharmaceuticals Inc 16.73%$ 16.735 millions
Invo Fertility Inc 16.73%$ 16.732 millions
Pro dex Inc 16.65%$ 16.646 millions
Royalty Pharma Plc16.50%$ 16.499 millions
Acadia Pharmaceuticals Inc 16.40%$ 16.402 millions
Harvard Bioscience Inc 16.35%$ 16.352 millions
Alpha Pro Tech Ltd 15.76%$ 15.765 millions
Armata Pharmaceuticals Inc 15.72%$ 15.722 millions
Lifeward ltd 15.71%$ 15.706 millions


About Immucell Revenue Growth Rates (ICCC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Immucell Corp (CIK 811641).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-26-027668
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Immucell Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.